- Contact Us
- News and Events
- Investor Relations
- Locations and Facilities
- Careers
- About Our Site
- Accessibility Statement
- Privacy Policy
- Terms and Conditions
- For Employers and Medical Plan Providers
- For Pharmacists and Medical Professionals
- Drug Lists
- Drug Safety Alerts
- Emergency Response
- Mail Service Numbers, Forms and Information
- Specialty Pharmacy Services, Information and Forms
- Electronic Prior Authorization Information
- Clinical Drug Information
- Clinical Programs and Health Management
- Clinical Publications
- FAQs For Pharmacists and Pharmacy Staff
- Pharmacy Help Desk
- FAQs For Prescribers and Office Staff
- Contact Us | Health Professionals Only
Drug Safety Alerts
Relpax Patient-Level Recall
08/15/2019
On August 15, 2019, Pfizer Inc. (Pfizer) issued a notice regarding a patient-level recall of Relpax® (eletriptan hydrobromide) 40 mg tablets. This recall was issued because the product may not meet Pfizer’s in-house microbiological specification for the potential presence of Genus Pseudomonas and Burkholderia.
A complete list of the affected products and lot numbers is provided here:
This could be a health hazard or safety risk to patients who may be using product affected by this recall.
CVS Caremark® Response: Because of this action, CVS Caremark is contacting patients and prescribers to advise them of this recall. We are encouraging patients who are taking Relpax® 40 mg tablets to contact their prescriber.
For more information, health care providers may contact Pfizer Medical Information at 1-800-438-1985, Monday through Friday, 9:00 am to 5:00 pm (ET) and select option 3. You may also contact the United States Food and Drug Administration at 1‑888‑INFO-FDA (1‑888-463-6332) or visit https://www.fda.gov.